Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2015

01-06-2015 | Research Article

Significantly inhibitory effects of low molecular weight heparin (Fraxiparine) on the motility of lung cancer cells and its related mechanism

Authors: Guo-xing Zhong, Yi Gong, Chuan-jiang Yu, Shi-fei Wu, Qing-ping Ma, Yu Wang, Jiang Ren, Xue-chao Zhang, Wei-han Yang, Wen Zhu

Published in: Tumor Biology | Issue 6/2015

Login to get access

Abstract

Low molecular weight heparin (LMWH) improving the cancer survival has been attracting attention for many years. Our previous study found that LMWH (Fraxiparine) strongly downregulated the invasive, migratory, and adhesive ability of human lung adenocarcinoma A549 cells. Here, we aimed to further identify the antitumor effects and possible mechanisms of Fraxiparine on A549 cells and human highly metastatic lung cancer 95D cells. The ability of cell invasion, migration, and adhesion were measured by Transwell, Millicell, and MTT assays. FITC-labeled phalloidin was used to detect F-actin bundles in cells. Chemotactic migration was analyzed in a modified Transwell assay. Measurement of protein expression and phosphorylation activity of PI3K, Akt, and mTOR was performed with Western blot. Our studies found that Fraxiparine significantly inhibited the invasive, migratory, and adhesive characteristics of A549 and 95D cells after 24 h incubation and showed a dose-dependent manner. Fraxiparine influenced the actin cytoskeleton rearrangement of A549 and 95D cells by preventing F-actin polymerization. Moreover, Fraxiparine could significantly inhibit CXCL12-mediated chemotactic migration of A549 and 95D cells in a concentration-dependent manner. Furthermore, Fraxiparine might destroy the interaction between CXCL12-CXCR4 axis, then suppress the PI3K-Akt-mTOR signaling pathway in lung cancer cells. For the first time, our data indicated that Fraxiparine could significantly inhibit the motility of lung cancer cells by restraining the actin cytoskeleton reorganization, and its related mechanism might be through inhibiting PI3K-Akt-mTOR signaling pathway mediated by CXCL12-CXCR4 axis. Therefore, Fraxiparine would be a potential drug for lung cancer metastasis therapy.
Literature
1.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: Cancer J Clin. 2012;62(1):10–29.
2.
3.
Horlocker TT, Heit JA. Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthetic management. Anesth Analg. 1997;85(4):874–85.CrossRefPubMed
4.
Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(34):5490–505.CrossRef
5.
Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost: JTH. 2004;2(8):1266–71.CrossRefPubMed
6.
Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(10):2123–9.CrossRef
7.
Lazo-Langner A, Goss GD, Spaans JN, Rodger MA. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost: JTH. 2007;5(4):729–37.CrossRefPubMed
8.
von Delius S, Ayvaz M, Wagenpfeil S, Eckel F, Schmid RM, Lersch C. Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma. Thromb Haemost. 2007;98(2):434–9.
9.
Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28(1–2):15–33.CrossRefPubMed
10.
Chalkiadaki G, Nikitovic D, Katonis P, Berdiaki A, Tsatsakis A, Kotsikogianni I, et al. Low molecular weight heparin inhibits melanoma cell adhesion and migration through a PKCa/JNK signaling pathway inducing actin cytoskeleton changes. Cancer Lett. 2011;312(2):235–44.CrossRefPubMed
11.
Mellor P, Harvey JR, Murphy KJ, Pye D, O'Boyle G, Lennard TW, et al. Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo. Br J Cancer. 2007;97(6):761–8.CrossRefPubMedPubMedCentral
12.
Harvey JR, Mellor P, Eldaly H, Lennard TW, Kirby JA, Ali S. Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids? Clin Cancer Res: Off J Am Assoc Cancer Res. 2007;13(5):1562–70.CrossRef
13.
Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 2007;109(7):2708–17.PubMedPubMedCentral
14.
Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV, et al. Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood. 2009;113(22):5549–57.CrossRefPubMedPubMedCentral
15.
Lee YC, Lin HH, Hsu CH, Wang CJ, Chiang TA, Chen JH. Inhibitory effects of andrographolide on migration and invasion in human non-small cell lung cancer A549 cells via down-regulation of PI3K/Akt signaling pathway. Eur J Pharmacol. 2010;632(1–3):23–32.CrossRefPubMed
16.
Yu CJ, Ye SJ, Feng ZH, Ou WJ, Zhou XK, Li LD, et al. Effect of Fraxiparine, a type of low molecular weight heparin, on the invasion and metastasis of lung adenocarcinoma A549 cells. Oncol Lett. 2010;1(4):755–60.PubMedPubMedCentral
17.
Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood. 1999;94(11):3658–67.PubMed
18.
Kwiatkowska A, Kijewska M, Lipko M, Hibner U, Kaminska B. Downregulation of Akt and FAK phosphorylation reduces invasion of glioblastoma cells by impairment of MT1-MMP shuttling to lamellipodia and downregulates MMPs expression. Biochim Biophys Acta. 2011;1813(5):655–67.CrossRefPubMed
19.
Lee H, Kim JS, Kim E. Fucoidan from seaweed Fucus vesiculosus inhibits migration and invasion of human lung cancer cell via PI3K-Akt-mTOR pathways. PLoS One. 2012;7(11):e50624.CrossRefPubMedPubMedCentral
20.
Li H, Zhang B, Liu Y, Yin C. EBP50 inhibits the migration and invasion of human breast cancer cells via LIMK/cofilin and the PI3K/Akt/mTOR/MMP signaling pathway. Med Oncol. 2014;31(9):162.CrossRefPubMed
21.
Zhang L, Wang H, Zhu J, Ding K, Xu J. FTY720 reduces migration and invasion of human glioblastoma cell lines via inhibiting the PI3K/AKT/mTOR/p70S6K signaling pathway. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2014;35(11):10707–14.CrossRef
22.
Xing X, Zhang L, Wen X, Wang X, Cheng X, Du H, et al. PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway. Anti-Cancer Drugs. 2014;25(10):1129–40.CrossRefPubMedPubMedCentral
23.
24.
Su L, Zhang J, Xu H, Wang Y, Chu Y, Liu R, et al. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clin Cancer Res: Off J Am Assoc Cancer Res. 2005;11(23):8273–80.CrossRef
25.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA: Cancer J Clin. 2009;59(4):225–49.
26.
Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733–42.CrossRefPubMed
27.
Vicent S, Luis-Ravelo D, Anton I, Garcia-Tunon I, Borras-Cuesta F, Dotor J, et al. A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism. Cancer Res. 2008;68(7):2275–85.CrossRefPubMed
28.
Icli F, Akbulut H, Utkan G, Yalcin B, Dincol D, Isikdogan A, et al. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol. 2007;95(6):507–12.CrossRefPubMed
29.
Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(10):2130–5.CrossRef
30.
Nagy Z, Turcsik V, Blasko G. The effect of LMWH (nadroparin) on tumor progression. Pathol Oncol Res : POR. 2009;15(4):689–92.CrossRefPubMed
31.
Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group. Cancer. 1994;74(1):38–45.CrossRefPubMed
32.
Griffiths GO, Burns S, Noble SI, Macbeth FR, Cohen D, Maughan TS. FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer. BMC Cancer. 2009;9:355.CrossRefPubMedPubMedCentral
33.
Meyer G, Besse B, Friard S, Girard P, Corbi P, Azarian R, et al. Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: tinzaparin in lung tumours. Rev Mal Respir. 2011;28(5):654–9.CrossRefPubMed
34.
Bereczky B, Gilly R, Raso E, Vago A, Timar J, Tovari J. Selective antimetastatic effect of heparins in preclinical human melanoma models is based on inhibition of migration and microvascular arrest. Clin Exp Metastasis. 2005;22(1):69–76.CrossRefPubMed
35.
Hasan J, Shnyder SD, Clamp AR, McGown AT, Bicknell R, Presta M, et al. Heparin octasaccharides inhibit angiogenesis in vivo. Clin Cancer Res: Off J Am Assoc Cancer Res. 2005;11(22):8172–9.CrossRef
36.
Chen X, Xiao W, Qu X, Zhou S. The effect of dalteparin, a kind of low molecular weight heparin, on lung adenocarcinoma A549 cell line in vitro. Cancer Investig. 2008;26(7):718–24.CrossRef
37.
Abu Arab W, Kotb R, Sirois M, Rousseau E. Concentration- and time-dependent effects of enoxaparin on human adenocarcinomic epithelial cell line A549 proliferation in vitro. Can J Physiol Pharmacol. 2011;89(10):705–11.CrossRefPubMed
38.
Carmazzi Y, Iorio M, Armani C, Cianchetti S, Raggi F, Neri T, et al. The mechanisms of nadroparin-mediated inhibition of proliferation of two human lung cancer cell lines. Cell Prolif. 2012;45(6):545–56.CrossRefPubMed
39.
Park JW, Jeon OC, Kim SK, Al-Hilal TA, Jin SJ, Moon HT, et al. High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives. J Controlled Release : Off J Controlled Release Soc. 2010;148(3):317–26.CrossRef
40.
Yu L, Garg HG, Li B, Linhardt RJ, Hales CA. Antitumor effect of butanoylated heparin with low anticoagulant activity on lung cancer growth in mice and rats. Curr Cancer Drug Targets. 2010;10(2):229–41.CrossRefPubMed
41.
Bonello T, Coombes J, Schevzov G, Gunning P, Stehn J. Therapeutic targeting of the actin cytoskeleton in cancer. Cytoskeleton and Human Disease. Springer; 2012. p. 181-200.
42.
Giganti A, Friederich E. The actin cytoskeleton as a therapeutic target: state of the art and future directions. Prog Cell Cycle Res. 2003;5:511–25.PubMed
43.
Rao J, Li N. Microfilament actin remodeling as a potential target for cancer drug development. Curr Cancer Drug Targets. 2004;4(4):345–54.CrossRefPubMed
44.
Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2010;16(11):2927–31.CrossRef
45.
Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50–6.CrossRefPubMed
46.
Rubie C, Frick VO, Ghadjar P, Wagner M, Justinger C, Faust SK, et al. CXC receptor-4 mRNA silencing abrogates CXCL12-induced migration of colorectal cancer cells. J Transl Med. 2011;9:22.CrossRefPubMedPubMedCentral
47.
Gangadhar T, Nandi S, Salgia R. The role of chemokine receptor CXCR4 in lung cancer. Cancer Biol Therapy. 2010;9(6):409–16.CrossRef
48.
Sutton A, Friand V, Brule-Donneger S, Chaigneau T, Ziol M, Sainte-Catherine O, et al. Stromal cell-derived factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion. Mol Cancer Res : MCR. 2007;5(1):21–33.CrossRefPubMed
49.
Ma L, Qiao H, He C, Yang Q, Cheung CH, Kanwar JR, et al. Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer. Investig New Drugs. 2012;30(2):508–17.CrossRef
50.
David O, Jett J, LeBeau H, Dy G, Hughes J, Friedman M, et al. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res : Off J Am Assoc Cancer Res. 2004;10(20):6865–71.CrossRef
51.
Solomon B, Pearson RB. Class IA phosphatidylinositol 3-kinase signaling in non-small cell lung cancer. J Thorac Oncol: Off Publ Int Assoc Study of Lung Cancer. 2009;4(7):787–91.CrossRef
52.
Wojtalla A, Arcaro A. Targeting phosphoinositide 3-kinase signalling in lung cancer. Crit Rev Oncol/Hematol. 2011;80(2):278–90.CrossRef
53.
Sadir R, Baleux F, Grosdidier A, Imberty A, Lortat-Jacob H. Characterization of the stromal cell-derived factor-1alpha-heparin complex. J Biol Chem. 2001;276(11):8288–96.CrossRefPubMed
54.
Altundag K, Altundag O, Atik MA. Heparin and CXCL12 dimerization. J Clin Oncol : Off J Am Soc Clin Oncol. 2005;23(28):7248.CrossRef
55.
Simka M. Anti-metastatic activity of heparin is probably associated with modulation of SDF-1-CXCR4 axis. Med Hypotheses. 2007;69(3):709.CrossRefPubMed
Metadata
Title
Significantly inhibitory effects of low molecular weight heparin (Fraxiparine) on the motility of lung cancer cells and its related mechanism
Authors
Guo-xing Zhong
Yi Gong
Chuan-jiang Yu
Shi-fei Wu
Qing-ping Ma
Yu Wang
Jiang Ren
Xue-chao Zhang
Wei-han Yang
Wen Zhu
Publication date
01-06-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3117-8

Other articles of this Issue 6/2015

Tumor Biology 6/2015 Go to the issue

Research Article

Activation of M3 muscarinic receptor by acetylcholine promotes non-small cell lung cancer cell proliferation and invasion via EGFR/PI3K/AKT pathway

Research Article

Combined Runx2 and Snail overexpression is associated with a poor prognosis in breast cancer

Research Article

BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy

Research Article

High serum microRNA-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients

Review

The clinical value of ncRNAs in gastric cancer: a systematic review and meta-analyses

Research Commentary

Letter regarding Xiao WZ et al. entitled “Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis”
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits